Smoking Cessation
Conditions
Keywords
e-cigarette, nicotine dependence
Brief summary
The purpose of this study is to develop and test a series of booklets designed to assist smokers of tobacco cigarettes who are also using e-cigarettes (dual users) in quitting smoking and remaining smoke-free.
Detailed description
The first two aims of the present proposal are to adapt a validated self-help, smoking-cessation intervention to meet the needs of current dual users, and to test this new intervention in a randomized controlled trial (RCT). A third primary aim is to calculate the cost-effectiveness of the intervention. A secondary aim is to gather longitudinal data regarding the patterns of tobacco and e-cigarette use and the course of cessation of either product among dual users. Specific Aim 1. To create a minimal smoking-cessation intervention for current dual users of tobacco cigarettes and e-cigarettes (Study I). The intervention will comprise a series of booklets and pamphlets modeled after the Forever Free booklets found to be successful at producing long-term abstinence among the general population of smokers, but adapted to the special needs, circumstances, and risk factors of dual users. Validated methodologies used for adapting the intervention mirror those used in our prior smoking cessation studies, and reflect systematic approaches across two-phases informed by individual interviews and learner verification methodologies. The intervention will provide assistance for smoking cessation, and also encourage users to taper and eventually terminate their e-cigarette use as per traditional nicotine replacement therapy (NRT). The end product of Study I will be a series of booklets tentatively titled, If You Vape: Guide to Quitting Smoking, available both in printed and electronic formats. Specific Aim 2. To evaluate the efficacy of the intervention via a randomized, controlled clinical trial of current dual users (Study II). We will compare the intervention developed under Specific Aim 1 with both an assessment-only condition and a generic self-help condition comprising existing smoking cessation booklets. We hypothesize that recipients of our targeted If You Vape booklets will show higher rates of tobacco abstinence at 6, 12, 18, and 24 months after enrollment, as compared to both comparison conditions. A secondary hypothesis is that the new intervention will produce higher rates of abstinence from e-cigarettes themselves. To identify mechanism of change, we will also test several a priori moderator and mediator variables, including gender, socio-economic status, motivation to quit, nicotine dependence, e-cigarette expectancies, and magnitude of e-cigarette use (frequency, dosage). Specific Aim 3. To calculate and compare the cost-effectiveness of the interventions. Cost- effectiveness data are vital for evaluating the real-world feasibility of an intervention. Small improvements in treatment efficacy may not be justified if they require substantially greater cost. We will compare the interventions not only on outcome efficacy, but on cost-effectiveness with respect to cost per incremental cessation and expected life-years saved.
Interventions
The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
Sponsors
Study design
Eligibility
Inclusion criteria
* Study I - First Phase - No Longer Recruiting * Greater than 1 year history of daily smoking * 1 month or more of e-cigarette use * Able to speak and read English * (1) current dual users (of tobacco cigarettes and e-cigarettes) without interest in quitting smoking; (2) current dual users who have attempted, but not quit smoking; (3) current e-cigarette users who have successfully quit smoking; and (4) former dual users who have quit both products. * Study I - Second Phase - No Longer Recruiting * Current dual users (of tobacco cigarettes and e-cigarettes) * Smoking at least one cigarette per day over the past year * Using e-cigarettes at least once per week over the past month * Not currently enrolled in a face-to-face smoking cessation program * Able to speak and read English * Study II - No Longer Recruiting * Current dual users (of tobacco cigarettes and e-cigarettes) * Smoking at least one cigarette per week over the past year * Using e-cigarettes at least once per week over the past month * Not currently enrolled in a face-to-face smoking cessation program * Able to speak and read English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Smoking Abstinence | 18 months & 24 months post study enrollment | Percentage rate of smoking abstinence for participants who received If You Vape booklets, compared to: A) participants in an assessment-only condition; B) participants in a generic self-help condition comprising existing smoking cessation booklets. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the Use of Tobacco Products | 18 and 24 months post study enrollment | As a surveillance study, investigators will track changes in the use of both tobacco cigarettes and e-cigarettes over time for ASSESS group only |
Other
| Measure | Time frame | Description |
|---|---|---|
| Study 2: Cost Effectiveness | 18 months and 24 months after study recruitment | Cost per incremental cessation will be measured using USD spent on the self help materials provided to the participants in the Generic and eTarget groups at 18 months and 24 months. \*\*\*Total cost was calculated for the intervention and not calculated as per participant cost |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Assessment Only (ASSESS) Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time. | 575 |
| Generic Self-Help (GENERIC) This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
GENERIC: The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study. | 1,154 |
| Targeted Self-Help (eTARGET) Participants in this condition will receive the intervention created as the product of Study I.
eTARGET: The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets. | 1,167 |
| Total | 2,896 |
Baseline characteristics
| Characteristic | Assessment Only (ASSESS) | Generic Self-Help (GENERIC) | Targeted Self-Help (eTARGET) | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 30 Participants | 69 Participants | 76 Participants | 175 Participants |
| Age, Categorical >=65 years | 6 Participants | 12 Participants | 6 Participants | 24 Participants |
| Age, Categorical Between 18 and 65 years | 539 Participants | 1073 Participants | 1085 Participants | 2697 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 65 Participants | 87 Participants | 89 Participants | 241 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 510 Participants | 1067 Participants | 1078 Participants | 2655 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 15 Participants | 27 Participants | 11 Participants | 53 Participants |
| Race (NIH/OMB) Asian | 5 Participants | 9 Participants | 9 Participants | 23 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 35 Participants | 41 Participants | 86 Participants |
| Race (NIH/OMB) More than one race | 27 Participants | 57 Participants | 64 Participants | 148 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 3 Participants | 8 Participants | 7 Participants | 18 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 6 Participants | 10 Participants | 18 Participants |
| Race (NIH/OMB) White | 513 Participants | 1012 Participants | 1025 Participants | 2550 Participants |
| Region of Enrollment United States | 575 participants | 1154 participants | 1167 participants | 2896 participants |
| Sex: Female, Male Female | 207 Participants | 435 Participants | 424 Participants | 1066 Participants |
| Sex: Female, Male Male | 368 Participants | 719 Participants | 743 Participants | 1830 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Rate of Smoking Abstinence
Percentage rate of smoking abstinence for participants who received If You Vape booklets, compared to: A) participants in an assessment-only condition; B) participants in a generic self-help condition comprising existing smoking cessation booklets.
Time frame: 18 months & 24 months post study enrollment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ASSESS at 18 Months | Rate of Smoking Abstinence | 33 percentage of participants |
| ASSESS at 24 Months | Rate of Smoking Abstinence | 40 percentage of participants |
| GENERIC at 18 Months | Rate of Smoking Abstinence | 37 percentage of participants |
| GENERIC at 24 Months | Rate of Smoking Abstinence | 42 percentage of participants |
| eTARGET at 18 Months | Rate of Smoking Abstinence | 38 percentage of participants |
| eTARGET at 24 Months | Rate of Smoking Abstinence | 42 percentage of participants |
Changes in the Use of Tobacco Products
As a surveillance study, investigators will track changes in the use of both tobacco cigarettes and e-cigarettes over time for ASSESS group only
Time frame: 18 and 24 months post study enrollment
Population: For this outcome measure, only the ASSESS group was analyzed for naturalistic changes in smoking and e-cigarette use over time.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ASSESS at 18 Months | Changes in the Use of Tobacco Products | 33 percentage of participants |
| ASSESS at 24 Months | Changes in the Use of Tobacco Products | 40 percentage of participants |
| GENERIC at 18 Months | Changes in the Use of Tobacco Products | 27 percentage of participants |
| GENERIC at 24 Months | Changes in the Use of Tobacco Products | 32 percentage of participants |
Study 2: Cost Effectiveness
Cost per incremental cessation will be measured using USD spent on the self help materials provided to the participants in the Generic and eTarget groups at 18 months and 24 months. \*\*\*Total cost was calculated for the intervention and not calculated as per participant cost
Time frame: 18 months and 24 months after study recruitment
Population: Participant groups evaluated at 18 and 24 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ASSESS at 18 Months | Study 2: Cost Effectiveness | 0 USD |
| ASSESS at 24 Months | Study 2: Cost Effectiveness | 0 USD |
| GENERIC at 18 Months | Study 2: Cost Effectiveness | 1535 USD |
| GENERIC at 24 Months | Study 2: Cost Effectiveness | 2369 USD |
| eTARGET at 18 Months | Study 2: Cost Effectiveness | 1000 USD |
| eTARGET at 24 Months | Study 2: Cost Effectiveness | 2253 USD |